title: [Assessment of psoriatic nail lesions therapy by means of nail psoriasis severity index].
abstract: The problem of psoriatic nail lesions is known for a long time. According to various authors, psoriatic onychodystrophy has been diagnosed in 15-78% of patients with psoriasis. At the same time, we know that the treatment of psoriatic nail lesions is not always successful.   The aim of the study was to evaluate the therapeutic efficacy of the drug onypso in the complex treatment of patients with psoriasis by means of NAPSI index.  We observed 39 patients with psoriasis (20 men and 19 women at the age of 19 to 65 years with disease duration of 1 year to 25 years). The distribution of clinical manifestations of psoriatic onychodystrophy was as follow: thimble symptom -150 plates, subungual hyperkeratosis lesion type - 90 plates, onycholysis lesion type was observed in 50 plates.   As a systemic treatment we used the cytostatic agent methotrexate - parenteral administration of 25 mg (once a week). In duration of total treatment course the patient received 90 -120 mg. Local treatment was provided by means of varnish onypso (once a day for 6 months).   The survey revealed that at 7 weeks of treatment there was a 25 % reduction of initial value of NAPSI index, at the end of 14 weeks of therapy the above mentioned index was reduced for 50 % and at the 24 weeks for 75% respectively. It should be noted, that resolution of the cutaneous pathology was much faster than improvement of the structure of affected nail plates. Thus, drug onypso proposed for the specific treatment of nail lesions used in the complex therapy of patients with psoriasis is simple in use, accessible, compliant and highly effective.  As a conclusion, we can say that NAPSI method, used to determine the extent of lesions and the effectiveness of the therapy, can objectively evaluate the dynamics of clinical pathology of the nails and adequacy of used treatment.
authors.forename: N V
authors.initials: NV
authors.lastname: Tsiskarishvili
authors.forename: A G
authors.initials: AG
authors.lastname: Katsitadze
authors.forename: N I
authors.initials: NI
authors.lastname: Tsiskarishvili
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D017488:Hyperkeratosis, Epidermolytic / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009264:Nails, Malformed / Q000151:congenital* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D054039:Onycholysis / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D008727:Methotrexate